Mylan just took a blow to its 2017 hopes, and GSK got a boost: The FDA turned away Mylan's copycat version of the megablockbuster Advair.
A top Senate Democrat is throwing the weight of her office behind efforts to dig into opioid marketing practices.
Sanofi has seen enough of ED med Stendra, and it's walking away from its marketing partnership with maker Vivus.
The #FierceMadness DTC ad tournament is down to the final four with ads from BI, Allergan, Takeda and J&J still in the hunt.
Last October, Depomed switched up its board to appease activist Starboard Value. But Starboard didn’t stop there, and now Depmed has a new CEO.
How does Dupixent's list price square with Sanofi and Regeneron's vows for a fair cost? Pretty well, say analysts, number-crunchers and at least one…
The new multiple sclerosis med Roche has been anticipating—and the market shake-up other drugmakers have been dreading—is here.
Vertex is consolidating its R&D operations to three sites and shuttering one facility in Canada in a move that will claim 70 jobs there.
Set to launch at a price of $37,000, the atopic dermatitis therapy Dupixent (dupilumab) can now embark on its path to expected sales of $3 billion-plus.
Pfizer is looking to reclassify Viagra (sildenafil) as a pharmacy medicine in the U.K., almost a decade after its first OTC request.